Pharmacological Treatment of Gastritis: A Narrative Review with a Systematic Literature Search

Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut and liver Jg. 19; H. 6; S. 783 - 794
Hauptverfasser: Kim, Bokyung, Huh, Jung, Kim, Sang Gyun, Ahn, Ji Yong, Kim, Ji Won
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Korea (South) Gastroenterology Council for Gut and Liver 15.11.2025
거트앤리버 소화기연관학회협의회
Schlagworte:
Gastric Mucosa - drug effects
Gastritis - drug therapy
gastritis; pharmacologic treatment
Histamine H2 Antagonists - therapeutic use
Humans
Proton Pump Inhibitors - therapeutic use
내과학
Pharmacologic treatment
Gastritis
ISSN:1976-2283, 2005-1212, 2005-1212
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such treatments include mucoprotective agents, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CABs). Mucoprotective agents enhance gastric mucosal protection through multiple mechanisms, such as by promoting mucosal regeneration, reducing inflammation, and mitigating oxidative stress. Clinical trials have highlighted the effectiveness of these agents in promoting endoscopic healing and ameliorating symptoms, underscoring the clinical significance of these agents. H2RAs have been extensively used to manage gastritis due to their proven efficacy in reducing gastric acid secretion and promoting mucosal healing. Additionally, PPIs along with newer P-CABs provide robust acid suppression and have shown the ability to rapidly relieve symptoms, thus increasing the number of available treatment options. Since each pharmacological agent offers distinct therapeutic benefits, treatment should be selected based on an individual patient's needs and clinical context.
AbstractList Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such treatments include mucoprotective agents, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CABs). Mucoprotective agents enhance gastric mucosal protection through multiple mechanisms, such as by promoting mucosal regeneration, reducing inflammation, and mitigating oxidative stress. Clinical trials have highlighted the effectiveness of these agents in promoting endoscopic healing and ameliorating symptoms, underscoring the clinical significance of these agents. H2RAs have been extensively used to manage gastritis due to their proven efficacy in reducing gastric acid secretion and promoting mucosal healing. Additionally, PPIs along with newer P-CABs provide robust acid suppression and have shown the ability to rapidly relieve symptoms, thus increasing the number of available treatment options. Since each pharmacological agent offers distinct therapeutic benefits, treatment should be selected based on an individual patient’s needs and clinical context. KCI Citation Count: 0
Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such treatments include mucoprotective agents, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CABs). Mucoprotective agents enhance gastric mucosal protection through multiple mechanisms, such as by promoting mucosal regeneration, reducing inflammation, and mitigating oxidative stress. Clinical trials have highlighted the effectiveness of these agents in promoting endoscopic healing and ameliorating symptoms, underscoring the clinical significance of these agents. H2RAs have been extensively used to manage gastritis due to their proven efficacy in reducing gastric acid secretion and promoting mucosal healing. Additionally, PPIs along with newer P-CABs provide robust acid suppression and have shown the ability to rapidly relieve symptoms, thus increasing the number of available treatment options. Since each pharmacological agent offers distinct therapeutic benefits, treatment should be selected based on an individual patient’s needs and clinical context.
Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such treatments include mucoprotective agents, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CABs). Mucoprotective agents enhance gastric mucosal protection through multiple mechanisms, such as by promoting mucosal regeneration, reducing inflammation, and mitigating oxidative stress. Clinical trials have highlighted the effectiveness of these agents in promoting endoscopic healing and ameliorating symptoms, underscoring the clinical significance of these agents. H2RAs have been extensively used to manage gastritis due to their proven efficacy in reducing gastric acid secretion and promoting mucosal healing. Additionally, PPIs along with newer P-CABs provide robust acid suppression and have shown the ability to rapidly relieve symptoms, thus increasing the number of available treatment options. Since each pharmacological agent offers distinct therapeutic benefits, treatment should be selected based on an individual patient's needs and clinical context.
Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such treatments include mucoprotective agents, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CABs). Mucoprotective agents enhance gastric mucosal protection through multiple mechanisms, such as by promoting mucosal regeneration, reducing inflammation, and mitigating oxidative stress. Clinical trials have highlighted the effectiveness of these agents in promoting endoscopic healing and ameliorating symptoms, underscoring the clinical significance of these agents. H2RAs have been extensively used to manage gastritis due to their proven efficacy in reducing gastric acid secretion and promoting mucosal healing. Additionally, PPIs along with newer P-CABs provide robust acid suppression and have shown the ability to rapidly relieve symptoms, thus increasing the number of available treatment options. Since each pharmacological agent offers distinct therapeutic benefits, treatment should be selected based on an individual patient's needs and clinical context.Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs use, and autoimmune conditions. Pharmacological treatment aims primarily to heal the mucosa and resolve symptoms, and such treatments include mucoprotective agents, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), and potassium-competitive acid blockers (P-CABs). Mucoprotective agents enhance gastric mucosal protection through multiple mechanisms, such as by promoting mucosal regeneration, reducing inflammation, and mitigating oxidative stress. Clinical trials have highlighted the effectiveness of these agents in promoting endoscopic healing and ameliorating symptoms, underscoring the clinical significance of these agents. H2RAs have been extensively used to manage gastritis due to their proven efficacy in reducing gastric acid secretion and promoting mucosal healing. Additionally, PPIs along with newer P-CABs provide robust acid suppression and have shown the ability to rapidly relieve symptoms, thus increasing the number of available treatment options. Since each pharmacological agent offers distinct therapeutic benefits, treatment should be selected based on an individual patient's needs and clinical context.
Author Kim, Bokyung
Ahn, Ji Yong
Kim, Ji Won
Kim, Sang Gyun
Huh, Jung
Author_xml – sequence: 1
  givenname: Bokyung
  orcidid: 0000-0002-9143-9654
  surname: Kim
  fullname: Kim, Bokyung
  organization: Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Jung
  orcidid: 0000-0003-2533-7315
  surname: Huh
  fullname: Huh, Jung
  organization: Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
– sequence: 3
  givenname: Sang Gyun
  orcidid: 0000-0003-1799-9028
  surname: Kim
  fullname: Kim, Sang Gyun
  organization: Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea
– sequence: 4
  givenname: Ji Yong
  orcidid: 0000-0002-0030-3744
  surname: Ahn
  fullname: Ahn, Ji Yong
  organization: Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Ji Won
  orcidid: 0000-0002-1214-5544
  surname: Kim
  fullname: Kim, Ji Won
  organization: Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40675926$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003264479$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNo90ctOGzEUBmCroiqBdtEXqLxsKw34Mr51F6EWIkWlgqxrnbE9iWFmTO0JiLfvkEBWR7I__5b9n6CjIQ0Boc-UnAlCzPl66JggTKp3aMYIERVllB2hGTVKVoxpfoxOSrkjRFKmxAd0XBOphGFyhv7-2UDuwaUuraODDq9ygLEPw4hTiy-hjDmOsfzAc_wbcoYxPgZ8Ex5jeMJPcdxgwLfPZQz9tOPwMo5hMtsc8G2A7DYf0fsWuhI-vc5TtPr1c3VxVS2vLxcX82XlmNGqosIo7ykQU7O2Bs-cJ67lxAgPSnPtuBOSmUYToXktahIm32hKQQmQhJ-i7_vYIbf23kWbIO7mOtn7bOc3q4WlRClJ63rCiz32Ce7sQ4495Ofdid1CymsLeXpNF6yb_k7XQkrRmpo2DQDXykvvtZFNw-SU9XWf9ZDTv20oo-1jcaHrYAhpWyxnnDIpNacT_fJKt00f_OHity4m8G0PXE6l5NAeCCX2pWd76Jn_B_ael5o
Cites_doi 10.3346/jkms.2017.32.11.1807
10.3748/wjg.v12.i17.2756
10.1517/14656566.2012.747510
10.3748/wjg.v28.i43.6078
10.1371/journal.pone.0175625
10.1097/00004836-198312001-00007
10.38212/2224-6614.1133
10.1016/S1590-8658(11)60593-8
10.1016/j.jep.2023.116986
10.1159/000106756
10.1007/s10620-011-1703-1
10.5056/jnm.2013.19.1.25
10.11405/nisshoshi.112.982
10.5009/gnl220446
10.1046/j.1440-1746.2003.03093.x
10.3748/wjg.v30.i48.5152
10.1007/s10620-006-9367-y
10.1111/j.1440-1746.2006.04721.x
10.1007/s40261-015-0329-z
10.5152/tjg.2014.7906
10.7704/kjhugr.2012.12.4.237
10.7704/kjhugr.2011.11.3.185
10.1111/1751-2980.12593
10.1016/S0163-7258(03)00015-9
10.1007/s12272-001-1175-8
10.1007/s10620-008-0255-5
10.1056/NEJM199803123381104
10.1046/j.1443-1661.2002.00199.x
10.4166/kjg.2017.70.1.4
10.3748/wjg.v10.i16.2379
10.5009/gnl20338
10.1097/MD.0000000000035926
10.1016/0002-9343(89)90156-3
10.3346/jkms.2011.26.8.1074
10.1136/bmj.l4898
10.1007/s00535-006-1952-5
10.1007/s10620-005-2800-9
10.3164/jcbn.11-10
10.5009/gnl220457
10.1155/2010/846353
10.3109/00365528909093113
10.29011/2638-003x.100036
10.7704/kjhugr.2021.0063
10.4168/aair.2011.3.2.128
10.9734/BJMMR/2013/3173
10.1016/S0016-5107(95)70043-9
10.1042/cs1000411
10.1136/gut.28.5.561
10.1016/0197-2456(95)00134-4
10.1055/s-0039-1681908
10.1016/0002-9343(85)90573-X
10.1016/0016-5085(86)90636-0
10.1007/s11894-008-0098-4
10.3164/jcbn.09-24
10.3109/00365528709090140
10.3109/00365528509089708
10.1097/00000478-199610000-00001
10.1016/0140-6736(92)92023-9
10.1080/17474124.2018.1378573
10.1097/00042737-200309000-00006
10.3892/etm.2021.10880
10.1038/ctg.2015.39
10.3346/jkms.2023.38.e115
10.3164/jcbn.2008041
10.7704/kjhugr.2013.13.3.173
10.1056/NEJM199803123381105
10.5551/jat.E615
10.1136/bmj.296.6616.195
10.1016/j.humpath.2004.12.008
10.1080/10286020.2018.1492565
10.1111/j.1440-1746.1991.tb01467.x
10.3164/jcbn.2007022
10.1007/s10620-007-0180-z
10.14715/cmb/2020.66.5.3
10.5056/jnm18029
10.1592/phco.21.1.60.34442
10.1136/gut.37.2.195
ContentType Journal Article
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
ACYCR
DOI 10.5009/gnl250267
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-1212
EndPage 794
ExternalDocumentID oai_kci_go_kr_ARTI_10776144
oai_doaj_org_article_c283845665f941bbaa387d6dd896bb26
40675926
10_5009_gnl250267
Genre Systematic Review
Journal Article
Review
GroupedDBID ---
5-W
8JR
AAKDD
AAYXX
ABDBF
ACUHS
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
F5P
GROUPED_DOAJ
GX1
HYE
HZB
OK1
RPM
CGR
CUY
CVF
ECM
EIF
NPM
7X8
9ZL
53G
85H
ID FETCH-LOGICAL-c2987-1597dd1a0942f4ad2cd0cf3095da7838c3c5629b805834540e97db811a75a603
IEDL.DBID DOA
ISSN 1976-2283
2005-1212
IngestDate Thu Nov 20 03:11:12 EST 2025
Mon Nov 17 19:31:39 EST 2025
Fri Jul 18 18:38:32 EDT 2025
Mon Nov 17 02:00:37 EST 2025
Thu Nov 20 00:28:37 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Pharmacologic treatment
Gastritis
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2987-1597dd1a0942f4ad2cd0cf3095da7838c3c5629b805834540e97db811a75a603
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ORCID 0000-0002-0030-3744
0000-0002-1214-5544
0000-0003-2533-7315
0000-0003-1799-9028
0000-0002-9143-9654
OpenAccessLink https://doaj.org/article/c283845665f941bbaa387d6dd896bb26
PMID 40675926
PQID 3231266831
PQPubID 23479
PageCount 12
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10776144
doaj_primary_oai_doaj_org_article_c283845665f941bbaa387d6dd896bb26
proquest_miscellaneous_3231266831
pubmed_primary_40675926
crossref_primary_10_5009_gnl250267
PublicationCentury 2000
PublicationDate 2025-11-15
PublicationDateYYYYMMDD 2025-11-15
PublicationDate_xml – month: 11
  year: 2025
  text: 2025-11-15
  day: 15
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Gut and liver
PublicationTitleAlternate Gut Liver
PublicationYear 2025
Publisher Gastroenterology Council for Gut and Liver
거트앤리버 소화기연관학회협의회
Publisher_xml – name: Gastroenterology Council for Gut and Liver
– name: 거트앤리버 소화기연관학회협의회
References ref13
ref57
ref12
ref56
ref15
ref59
ref14
ref58
ref53
ref52
ref11
ref55
ref10
ref54
ref17
ref16
ref19
ref18
ref51
ref50
ref46
ref45
ref48
ref47
ref42
ref86
ref41
ref85
ref44
ref88
ref43
ref87
ref49
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref82
ref81
ref40
ref84
ref83
ref80
ref35
ref79
ref34
ref78
ref37
ref36
ref31
ref75
ref30
ref74
ref33
ref77
ref32
ref76
ref2
ref1
ref39
ref38
ref71
ref70
ref73
ref72
ref24
ref68
ref23
ref67
ref26
ref25
ref69
ref20
ref64
ref63
ref22
ref66
ref21
ref65
ref28
ref27
ref29
ref60
ref62
ref61
References_xml – ident: ref17
  doi: 10.3346/jkms.2017.32.11.1807
– ident: ref66
  doi: 10.3748/wjg.v12.i17.2756
– ident: ref3
  doi: 10.1517/14656566.2012.747510
– ident: ref14
  doi: 10.3748/wjg.v28.i43.6078
– ident: ref50
  doi: 10.1371/journal.pone.0175625
– ident: ref72
  doi: 10.1097/00004836-198312001-00007
– ident: ref82
  doi: 10.38212/2224-6614.1133
– ident: ref2
  doi: 10.1016/S1590-8658(11)60593-8
– ident: ref28
  doi: 10.1016/j.jep.2023.116986
– ident: ref43
  doi: 10.1159/000106756
– ident: ref15
  doi: 10.1007/s10620-011-1703-1
– ident: ref68
  doi: 10.5056/jnm.2013.19.1.25
– ident: ref12
  doi: 10.11405/nisshoshi.112.982
– ident: ref20
  doi: 10.5009/gnl220446
– ident: ref67
  doi: 10.1046/j.1440-1746.2003.03093.x
– ident: ref18
  doi: 10.3748/wjg.v30.i48.5152
– ident: ref39
  doi: 10.1007/s10620-006-9367-y
– ident: ref78
  doi: 10.1111/j.1440-1746.2006.04721.x
– ident: ref34
  doi: 10.1007/s40261-015-0329-z
– ident: ref1
  doi: 10.5152/tjg.2014.7906
– ident: ref16
  doi: 10.7704/kjhugr.2012.12.4.237
– ident: ref53
– ident: ref13
  doi: 10.3748/wjg.v28.i43.6078
– ident: ref47
  doi: 10.7704/kjhugr.2011.11.3.185
– ident: ref61
– ident: ref6
  doi: 10.1111/1751-2980.12593
– ident: ref76
  doi: 10.1016/S0163-7258(03)00015-9
– ident: ref44
– ident: ref29
  doi: 10.1007/s12272-001-1175-8
– ident: ref35
  doi: 10.1007/s10620-008-0255-5
– ident: ref81
  doi: 10.1056/NEJM199803123381104
– ident: ref8
  doi: 10.1046/j.1443-1661.2002.00199.x
– ident: ref69
  doi: 10.4166/kjg.2017.70.1.4
– ident: ref30
  doi: 10.3748/wjg.v10.i16.2379
– ident: ref19
  doi: 10.5009/gnl20338
– ident: ref21
  doi: 10.1097/MD.0000000000035926
– ident: ref54
  doi: 10.1016/0002-9343(89)90156-3
– ident: ref32
  doi: 10.3346/jkms.2011.26.8.1074
– ident: ref23
  doi: 10.1136/bmj.l4898
– ident: ref42
  doi: 10.1007/s00535-006-1952-5
– ident: ref33
  doi: 10.1007/s10620-005-2800-9
– ident: ref38
  doi: 10.3164/jcbn.11-10
– ident: ref71
– ident: ref88
  doi: 10.5009/gnl220457
– ident: ref87
  doi: 10.1155/2010/846353
– ident: ref55
  doi: 10.3109/00365528909093113
– ident: ref9
  doi: 10.29011/2638-003x.100036
– ident: ref24
  doi: 10.7704/kjhugr.2021.0063
– ident: ref77
  doi: 10.4168/aair.2011.3.2.128
– ident: ref45
– ident: ref79
  doi: 10.9734/BJMMR/2013/3173
– ident: ref60
– ident: ref51
– ident: ref48
– ident: ref5
  doi: 10.1016/S0016-5107(95)70043-9
– ident: ref64
  doi: 10.1042/cs1000411
– ident: ref7
  doi: 10.1136/gut.28.5.561
– ident: ref22
  doi: 10.1016/0197-2456(95)00134-4
– ident: ref59
  doi: 10.1055/s-0039-1681908
– ident: ref57
  doi: 10.1016/0002-9343(85)90573-X
– ident: ref52
  doi: 10.1016/0016-5085(86)90636-0
– ident: ref85
  doi: 10.1007/s11894-008-0098-4
– ident: ref36
  doi: 10.3164/jcbn.09-24
– ident: ref74
  doi: 10.3109/00365528709090140
– ident: ref70
  doi: 10.3109/00365528509089708
– ident: ref10
  doi: 10.1097/00000478-199610000-00001
– ident: ref75
  doi: 10.1016/0140-6736(92)92023-9
– ident: ref26
  doi: 10.1080/17474124.2018.1378573
– ident: ref56
  doi: 10.1097/00042737-200309000-00006
– ident: ref49
  doi: 10.3892/etm.2021.10880
– ident: ref84
  doi: 10.1038/ctg.2015.39
– ident: ref25
  doi: 10.3346/jkms.2023.38.e115
– ident: ref41
  doi: 10.3164/jcbn.2008041
– ident: ref46
  doi: 10.7704/kjhugr.2013.13.3.173
– ident: ref80
– ident: ref63
  doi: 10.1056/NEJM199803123381105
– ident: ref37
  doi: 10.5551/jat.E615
– ident: ref73
  doi: 10.1136/bmj.296.6616.195
– ident: ref4
  doi: 10.1016/j.humpath.2004.12.008
– ident: ref27
  doi: 10.1080/10286020.2018.1492565
– ident: ref11
  doi: 10.1111/j.1440-1746.1991.tb01467.x
– ident: ref65
  doi: 10.3164/jcbn.2007022
– ident: ref40
  doi: 10.1007/s10620-007-0180-z
– ident: ref86
  doi: 10.14715/cmb/2020.66.5.3
– ident: ref83
  doi: 10.5056/jnm18029
– ident: ref58
  doi: 10.1592/phco.21.1.60.34442
– ident: ref62
  doi: 10.1136/gut.37.2.195
– ident: ref31
SSID ssj0061275
Score 2.3759973
SecondaryResourceType review_article
Snippet Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as infection, nonsteroidal...
Gastritis, characterized by gastric mucosal inflammation, is a common gastrointestinal disorder with diverse etiologies, such as Helicobacter pylori infection,...
SourceID nrf
doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
StartPage 783
SubjectTerms Gastric Mucosa - drug effects
Gastritis - drug therapy
gastritis; pharmacologic treatment
Histamine H2 Antagonists - therapeutic use
Humans
Proton Pump Inhibitors - therapeutic use
내과학
Title Pharmacological Treatment of Gastritis: A Narrative Review with a Systematic Literature Search
URI https://www.ncbi.nlm.nih.gov/pubmed/40675926
https://www.proquest.com/docview/3231266831
https://doaj.org/article/c283845665f941bbaa387d6dd896bb26
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003264479
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Gut and Liver, 2025, 19(6), , pp.783-794
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2005-1212
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0061275
  issn: 1976-2283
  databaseCode: DOA
  dateStart: 20070101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwEB5RhKpeUKEP0hbkll4j8tj40Rug0iLRFRKrak-1xi-EQFmULf39Hdu7oZeql54iRUlsfRN7vslMvgH4SNudqz0tJO7jLzm1caUJAUuFHRox4dwmMZ3vF2I6lfO5uvyj1VesCcvywBm4I0v-T5KX511Q9CiD2ErhuHNScWOaJLZdCbUOpvIezKNseconC15GgZesKdQRoTi67u_I7TepsfyjJ0qC_eRf-iH8nWsmn3P2HLZXZJEd50nuwIbvd-Hpt1U6_AX8uHwUno5gs9m6bJwtAvuCy6S0v_zEjtkUh6zxzXI2gMUPsAzZ1ajkzC5GhWWWi5Bfwuzs8-z0a7lqmFDaRtFmQdREOFcjhWxNmKBrrKtsaIlFORQEo20t0R1lZNXJNkrvebreyLpG0SGv2lew2S96vwfMqC6g8KGaoKcA2qAQNIBpOqNiJtQV8GGNnb7PshiawokIsB4BLuAkojpeEJWs0wmyr17ZV__LvgUckk30rb1J98fj9ULfDpr4_jmNKUQMaQt4v7aZpvURkx7Y-8XDUrdEYImEyLYu4HU25jihSQyXVMPf_I-JvoVnTewNHEsEu3ew-XN48PuwZX-RnYcDeCLm8iC9pL8BgZTnng
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacological+Treatment+of+Gastritis%3A+A+Narrative+Review+with+a+Systematic+Literature+Search&rft.jtitle=Gut+and+liver&rft.au=Kim+Bokyung&rft.au=Huh+Jung&rft.au=Kim+Sang+Gyun&rft.au=Ahn+Ji+Yong&rft.date=2025-11-15&rft.pub=%EA%B1%B0%ED%8A%B8%EC%95%A4%EB%A6%AC%EB%B2%84+%EC%86%8C%ED%99%94%EA%B8%B0%EC%97%B0%EA%B4%80%ED%95%99%ED%9A%8C%ED%98%91%EC%9D%98%ED%9A%8C&rft.issn=1976-2283&rft.eissn=2005-1212&rft.spage=783&rft.epage=794&rft_id=info:doi/10.5009%2Fgnl250267&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_10776144
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1976-2283&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1976-2283&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1976-2283&client=summon